Constraint-Aware Corrective Memory for Language-Based Drug Discovery Agents

arXiv cs.AI / 4/13/2026

💬 OpinionSignals & Early TrendsIdeas & Deep AnalysisModels & Research

Key Points

  • The paper argues that autonomous language-based drug discovery agents should be evaluated and controlled at the whole candidate set level, since success depends on joint protocol-level properties like set size, diversity, binding quality, and developability rather than single-step actions.
  • It identifies a reliability issue in existing systems: they rely on long raw histories and under-specified self-reflection, which makes failure localization imprecise and planner-facing agent states increasingly noisy.
  • The proposed CACM framework adds constraint-aware protocol auditing with a grounded diagnostician to diagnose protocol violations using multimodal evidence (task requirements, pocket context, and candidate-set evidence).
  • CACM produces actionable remediation hints and biases subsequent actions toward the most relevant correction, while keeping planning context compact via a memory design with static, dynamic, and corrective channels plus compression before write-back.
  • Experiments report a 36.4% improvement in target-level success rate over the state of the art, suggesting that better diagnosis and more efficient agent state can be as important as stronger molecular tools.

Abstract

Large language models are making autonomous drug discovery agents increasingly feasible, but reliable success in this setting is not determined by any single action or molecule. It is determined by whether the final returned set jointly satisfies protocol-level requirements such as set size, diversity, binding quality, and developability. This creates a fundamental control problem: the agent plans step by step, while task validity is decided at the level of the whole candidate set. Existing language-based drug discovery systems therefore tend to rely on long raw history and under-specified self-reflection, making failure localization imprecise and planner-facing agent states increasingly noisy. We present CACM (Constraint-Aware Corrective Memory), a language-based drug discovery framework built around precise set-level diagnosis and a concise memory write-back mechanism. CACM introduces protocol auditing and a grounded diagnostician, which jointly analyze multimodal evidence spanning task requirements, pocket context, and candidate-set evidence to localize protocol violations, generate actionable remediation hints, and bias the next action toward the most relevant correction. To keep planning context compact, CACM organizes memory into static, dynamic, and corrective channels and compresses them before write-back, thereby preserving persistent task information while exposing only the most decision-relevant failures. Our experimental results show that CACM improves the target-level success rate by 36.4% over the state-of-the-art baseline. The results show that reliable language-based drug discovery benefits not only from more powerful molecular tools, but also from more precise diagnosis and more economical agent states.